Antimicrobial Reference Laboratory

Size: px
Start display at page:

Download "Antimicrobial Reference Laboratory"

Transcription

1 Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB

2 Guideline Ranges 2018 Aminoglycosides Gentamicin Tobramycin (Once-daily) a All s on 2nd- 4th dose; earlier if changing renal function or other risk factors. Post >10 mg/l or 8 h post (4.5 mg/kg) mg/l or follow Hartford nomogram (but note this is for 7 mg/kg) Gentamicin (Once-daily 5 mg/kg) b Gentamicin Tobramycin (BD or TDS) c-d Neonatal sepsis All s on 2nd- 4th dose; earlier if changing renal function or other risk factors. Amikacin (Once-daily) a Amikacin (BD or TDS) c Streptomycin All s after 2nd- (7.5 mg/kg BD) d-e 4th dose. Pre < 2mg/L BUT <1 mg/l after 3 rd dose Post >8mg/L Gm- pneumonia Pre <2 mg/l Post >7 mg/l Infective endocarditis (IE) Post 3-5 mg/l Pre <5 mg/l Post >35 mg/l Pre <10 mg/l Post mg/l Infective endocarditis Pre <3.0 mg/l Post mg/l * Assuming initial results are within the expected range a Nicolau et al Antimicrobial s & Chemotherapy 39: b NICE Clinical Guideline 149, c British National Formulary, Edition section d Elliott et al Journal of Antimicrobial Chemotherapy 54: e Note: these are different to the AHA Scientific Statement ranges. Baddour et al Circulation 132:

3 Guideline Ranges 2018 Glycopeptides/Lipopeptides/Oxazolidinones Vancomycin a-d All s on >2-4 days therapy. Patients receiving other nephrotoxic drugs. Assay at 2nd-4th dose. Pre dose mg/l but mg/l in complicated infection OR Steady state during continuous infusion mg/l Teicoplanin e-f Daptomycin g Linezolid (600mg BD) h-i Staph. aureus a) Skin and soft tissue infection b) Bone and Joint infection d) Infective endocarditis e) OPAT on 25 mg/kg 3x per week Patients with CPK elevation, high dose therapy (>6 mg/kg) or renal impairment Patients on long-term therapy (>28d) or if on agents with potential drug interactions Pre but <60 mg/l Pre but <60 mg/l Pre but <60 mg/l Pre mg/l Pre dose 5-20 mg/l Or Pre dose 10-20mg/L in severe sepsis Pre 2-8 mg/l Post mg/l * Assuming initial results are within the expected range a Jeffres et al Chest 130: Lodise et al Antimicrobial s & Chemotherapy 52: b British National Formulary Number 55. Rybak et al Am J Health-Syst Pharm. 66: c Ingram et al Journal of Antimicrobial Chemotherapy 62: d Wysocki et al, Antimicrobial s and Chemotherapy 45: e Teicoplanin: Summary of Product Characteristics European Medicines Agency. Assessment report: Targocid and associated names EMEA/H/A-30/1301. European Medicines Agency. f Lamont et al, Journal of Antimicrobial Chemotherapy 64: g Bhavnani et al Clinical Infectious Diseases 50: Falcone et al J. Infection Chemotherapy 19 :732-9, DiPaolo et al Int J. Antimicrobial s 42 :250-5, Falcone et al CID 57 : , Reiber et al Therapeutic Drug Monitoring, 37 : h Pea et al JAC 67: Dong et al Eur J. Clinical Microbiology & Infectious Diseases, Epub 12/02/14 i Matsumoto et al International Journal of Antimicrobial s 44: Cattaneo et al Expert Opin Drug Metab. Toxicol. 12:

4 Guideline Ranges 2018 Antifungal agents Flucytosine a Isavuconazole e Itraconazole a-b Routine within 72h of starting therapy. Not routinely monitored but may be useful in complex cases or in renal impairment Routine in 1 st week of therapy. Measure 4-7 days after starting therapy Pre mg/l Post mg/l Pre dose concentrations <20 mg/l have been associated with treatment failure and emergence of resistance. Post dose concentrations >100 mg/l have been associated with toxicity. Pre 1-4 mg/l By Chromatographic assay Prophylaxis pre mg/l Therapy pre mg/L NB. These guidelines are different to those achieved by bio-assay. Fluconazole a Posaconazole a-c Voriconazole a,b,d Not routinely monitored but may be useful in complex cases or renal failure Routine in majority of s. Measure 3-8 days after starting therapy Routinely within 5d of starting therapy AUC:MIC ratio of >100, call for advice on sampling. Prophylaxis: Pre mg/l Therapy: Pre mg/l Prophylaxis and therapy Pre mg/l Assuming initial results are within the expected range a Vermes et al Journal of Antimicrobial Chemotherapy 46: Ashbee et al J. Antimicrobial Chemotherapy 69: b Andes et al Antimicrobial s and Chemotherapy 53: Dolton et al Current Opinion in Infectious Diseases 27: Chau et al Intern Med J 44:1368. c Dolton et al Antimicrobial s and Chemotherapy 56: Dekkers et al Curr Fung Infect Rep 10:51-61 d Pascual et al Clinical Infectious Diseases 55: e Peixoto et al JCM 52:

5 Guideline Ranges 2018 Streptomycin b (15 mg/kg OD) Streptomycin c (25 mg/kg BIW) Rifampicin c Ethambutol c Rifabutin d Levofloxacin d Cycloserine d Moxifloxacin d Linezolid e (600 mg OD oral) (600 mg BD oral) s used in Mycobacterial infection a All s after 2nd- 4th dose. All s after 2nd- 4th dose. Patients with poor clinical Patients with poor clinical or significant renal dysfunction Patients who fail to respond to treatment. Patients on agents with P450 interactions Patients being treated for MDR TB. All s after 4th- 6th dose. Patients being treated for MDR TB. Patients being treated for MDR TB. Pre <5 mg/l in <50y s in >50y s Post mg/l Post mg/l Pre <0.5mg/L Post <4mg/L sub-therapeutic Post mg/l usually adequate Post 8-24mg/L ideal Post 2-6 mg/l Pre <0.1mg/L Post mg/l Pre mg/l Post 8-13 mg/l Pre 10-20mg/L Post (3-4h) 20-35mg/L Pre mg/l Post 3-5 mg/l Pre <5mg/L Post 12-26mg/L Pre 2-8 mg/l Post mg/l 7-28d 7-28d * Assuming initial results are within the expected range; BIW: twice a week a Assuming that s are on standard (usually daily) therapy, for s on intermittent therapy please call to discuss expected levels as these will vary depending on dosing regimen used. b British National Formulary, Edition section c Peloquin Microbiol Spectrum 5:1-8. Pasipanodya et al J. Infectious Diseases 208: d Holland et al Pharmacotherapy 29: Srivastava et al European Respiratory Journal, 42: Ramachandran et al, 2015, Drug Safety, 38: Peloquin Microbiol Spectrum 5:1-8. Hwang et al Int J. Tuberc Lung Dis 17: Park.et al AAcC 59: e Schecter et al CID 50: 49-55; McGee et al Antimicrobial s & Chemotherapy 53: Dong et al Eur J. Clinical Microbiology & Infectious Diseases, Epub 12/02/14

6 Guideline Ranges 2018 Other agents Aciclovir and its metabolite CMMG f Ganciclovir a Chloramphenicol b Patients with renal impairment, on high dose therapy or exhibiting CNS effects Young children, renally impairment or unstable renal function All s but especially neonates. Pre dose CMMG <2.5 mg/l There are too many dose regimens used to give single guideline ranges and interpretation of aciclovir levels as these need to be specific but elevated CMMG levels are associated with increased risk of neurotoxicity: Pre mg/l Post 7-9 mg/l (ganciclovir) Post 5-7 mg/l (valganciclovir) Pre <10 mg/l Post (2h) mg/l 5-7 Co-trimoxazole d (sulphamethoxazole + trimethoprim) c High-dosage therapy (PCP) or renal impairment. Sulphamethoxazole: Pre <100 mg/l, Post but <200 mg/l Trimethoprim: Pre 5-7 mg/l, Post 5-10 but <20 mg/l Colistin e Patients on IV treatment Pre 2-4 mg/l Assuming initial results are within the expected range a Luck et al International Journal of Antimicrobial s 37: b British National Formulary, Edition section c Joos et al Antimicrobial s & Chemotherapy 39: d Brown Ann Int Care 4:13-22 e Nation et al Lancet Infectious Diseases S Gregorie et al Clin Pharmacokinet 56: f Hellden et al Nephrol. Dial. Transplant 18:

Antimicrobial Reference Laboratory

Antimicrobial Reference Laboratory Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2016-17 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB UK Aminoglycosides Gentamicin

More information

GUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition

GUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE GUIDELINES FOR USERS 17th Edition 2011 Earlier editions should be destroyed Antimicrobial Reference Laboratory Department of Medical Microbiology North

More information

SBUH Aminoglycoside Dosing Protocol

SBUH Aminoglycoside Dosing Protocol Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT

More information

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016 Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology

More information

Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults

Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job

More information

PK/PD degli antibiotici utilizzati nella sepsi

PK/PD degli antibiotici utilizzati nella sepsi PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill

More information

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes

More information

VANCOMYCIN DOSING AND MONITORING GUIDELINES

VANCOMYCIN DOSING AND MONITORING GUIDELINES VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal

More information

Clinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)

Clinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult) VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin

More information

MONTEFIORE MEDICAL CENTER

MONTEFIORE MEDICAL CENTER DEPARTMENT OF PHARMACY MONTEFIORE MEDICAL CENTER SUBJECT: MANUAL CODE: Restricted Drugs Policy, Antibiotic Restriction PH-R-5 DATE ISSUED: August, 1976 DATE REVISED: September 2000, October 2003, September

More information

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and 5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs

More information

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,

More information

Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence

Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs

More information

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg. AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough

More information

Challenges of therapeutic drug monitoring in paediatrics

Challenges of therapeutic drug monitoring in paediatrics Challenges of therapeutic drug monitoring in paediatrics Jim Gray Consultant Microbiologist Birmingham Children s Hospital, UK Overview Outline of the challenges Efficient TDM TDM in children: why and

More information

TDM of Aminoglycoside Antibiotics

TDM of Aminoglycoside Antibiotics TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic

More information

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW: Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic

More information

Pharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis

Pharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics

More information

AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES

AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES Approved: September 2017 AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee GENERAL COMMENTS Aminoglycosides (AG) include gentamicin,

More information

EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist

EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? 1.-CRRT : A «Lego» Module? 4.-Antibiotic Adaptation During Low Dose CRRT? 2.- CRRT + ECMO: What to do? 5.-

More information

Neutropenic Sepsis Guideline

Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt

More information

How To Use PK/PD Of Antifungal Drugs In Clinical Practice?

How To Use PK/PD Of Antifungal Drugs In Clinical Practice? How to use PK/PD of antifungal drugs in clinical practice? Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India How To

More information

EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING

EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley

More information

Antimicrobial Management of Febrile Neutropenic Sepsis

Antimicrobial Management of Febrile Neutropenic Sepsis Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:

More information

Endocardite infectieuse

Endocardite infectieuse Endocardite infectieuse 1. Raccourcir le traitement: jusqu où? 2. Proposer un traitement ambulatoire: à partir de quand? Endocardite infectieuse A B 90 P = 0.014 20 P = 0.0005 % infective endocarditis

More information

Joint Trust Guideline for the Use of Intravenous Vancomycin in Paediatrics

Joint Trust Guideline for the Use of Intravenous Vancomycin in Paediatrics A clinical guideline recommended For use in: All clinical areas where vancomycin is prescribed for Children aged 1 month to 16 years By: All medical, nursing, pharmacy, microbiology and phlebotomy paediatric

More information

The antibiotic dose and the obese ICU patient

The antibiotic dose and the obese ICU patient The antibiotic dose and the obese ICU patient Philippe Montravers, M.D., Ph.D. Anaesthesia and Surgical ICU CHU Bichat Claude Bernard Assistance Publique-Hôpitaux de Paris INSERM UMR 1152 University Paris

More information

ภก.วส นต กาต บ. Use of vancomycin is appropriate or acceptable. FDA Labeled Indication

ภก.วส นต กาต บ. Use of vancomycin is appropriate or acceptable. FDA Labeled Indication Quality improvement for DUE: Vancomycin, Linezolid and Daptomycin Vancomycin ภก.วส นต กาต บ Vancomycin. In: DRUGDEX System [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically.

More information

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin BSWH Pharmacist Continuing Education 2015 PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin Objectives Define basic pharmacodynamic and pharmacokinetic principles Describe

More information

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title

More information

Challenges in Therapeutic Drug Monitoring:

Challenges in Therapeutic Drug Monitoring: Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist

More information

La farmacologia in aiuto

La farmacologia in aiuto Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams

More information

Medication Dosing in CRRT

Medication Dosing in CRRT Medication Dosing in CRRT Linda Awdishu, PharmD, MAS Associate Clinical Professor of Pharmacy and Medicine Learning Objectives 1. List the pharmacokinetic changes associated with AKI. 2. Determine the

More information

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

More information

NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion

NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion Acute Sector NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion Co-ordinators: Gillian Macartney Fiona McDonald Specialist Antibiotic

More information

CLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel

CLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe

More information

Current challenges in triazole TDM

Current challenges in triazole TDM Current challenges in triazole TDM Isabel Spriet, PharmD PhD Clinical Pharmacology and Pharmacotherapy, University Hospitals Leuven & KU Leuven, Belgium Background Triazoles are the most widely prescribed

More information

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of

More information

Therapeutic Drug Monitoring

Therapeutic Drug Monitoring Therapeutic Drug Monitoring news from the laboratory Pieter Vermeersch, Steven Pauwels, Matthijs Oyaert Laboratory Medicine, UZ Leuven Overview 1. Introduction 2. Analytical methods 3. Testing on dry blood

More information

ICU Volume 11 - Issue 3 - Autumn Series

ICU Volume 11 - Issue 3 - Autumn Series ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective

More information

Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches

Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator

More information

Adult Institutional Pharmacokinetics Protocol

Adult Institutional Pharmacokinetics Protocol Adult Institutional Pharmacokinetics Protocol Policy Title: Clinical Pharmacokinetics (PK) Service Policy Policy Statement: It is the policy of UMHC that PK consult orders (for vancomycin or aminoglycosides)

More information

PROGRAM General Information

PROGRAM General Information Association for Quality Assessment in TDM and Clinical Toxicology Section of the Dutch Foundation for Quality Assessment in Medical Laboratories PROGRAM 2016 General Information P.O. Box 43100, 2504 AC

More information

ASHP Therapeutic Position Statements 623

ASHP Therapeutic Position Statements 623 ASHP Therapeutic Position Statements 623 Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society

More information

The Clinical Management of Hospital Acquired Pneumonia. NHS Ayrshire & Arran

The Clinical Management of Hospital Acquired Pneumonia. NHS Ayrshire & Arran The Clinical Management of Hospital Acquired Pneumonia Dr R G Masterton NHS Ayrshire & Arran What s new in HAP/VAP? Care bundles MRSA VAP Improving outcomes with current antimicrobial New antimicrobials

More information

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 584 608 doi: 10.1111/jcpt.12200 Review Article Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive

More information

Optimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology

Optimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»

More information

Cubicin A Guide to Dosing

Cubicin A Guide to Dosing Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections

More information

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal

More information

Infective Endocarditis Empirical therapy Antibiotic Guidelines. Contents

Infective Endocarditis Empirical therapy Antibiotic Guidelines. Contents Infective Endocarditis Empirical therapy Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Group Additional author(s): as above Authors Division: Division of Clinical

More information

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members) Infectious Diseases Society of America Emerging Infections Network Report for Query: Antimicrobial Drug Shortages 2016 Overall response rate: 701/1,597 (44%) physicians responded from 3/22/16 to 4/13/16.

More information

Aminoglycosides John A. Bosso, Pharm.D.

Aminoglycosides John A. Bosso, Pharm.D. AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly

More information

8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications

8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Dean Van Loo Pharm.D. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Steroids Biologics Antineoplastic Most data from cancer chemotherapy Bone marrow suppression Fever is the

More information

I am against to TDM in critically ill patient

I am against to TDM in critically ill patient TDM I am against to TDM in critically ill patient TDM of antifungals: where are we? Dr. Rafael Zaragoza Antifungal therapy in ICU; prophylaxis, pre-emptive and targeted Conflicts of interest: Pfizer Astellas

More information

ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS

ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS Version 4.0 Date ratified February 2009 Review date February 2011 Ratified by Authors Consultation Evidence

More information

Approved by: SMG Origination Date: 06/14 Expiration Date: 06/17 Review Date: Revision Date: POLICY and PROCEDURE Archived Date: Page 1 of 14

Approved by: SMG Origination Date: 06/14 Expiration Date: 06/17 Review Date: Revision Date: POLICY and PROCEDURE Archived Date: Page 1 of 14 POLICY and PROCEDURE Archived Date: Page 1 of 14 PURPOSE In order to provide consistent and optimal vancomycin and aminoglycoside dosing and monitoring, a pharmacokinetic (PK) service will be provided

More information

Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis

Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis Shaun E. Gleason, PharmD, MGS Associate Professor, Department of Clinical Pharmacy Director, Distance Degrees and Programs

More information

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2 Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following

More information

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.

More information

Evaluation of Vancomycin Continuous Infusion in Trauma Patients

Evaluation of Vancomycin Continuous Infusion in Trauma Patients OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential

More information

ORIGINAL ARTICLE DOI: (e) ISSN Online: (p) ISSN Print: Anand Kumar Singh 1, Poonam Verma 2. Sciences, Dehradun

ORIGINAL ARTICLE DOI: (e) ISSN Online: (p) ISSN Print: Anand Kumar Singh 1, Poonam Verma 2. Sciences, Dehradun ORIGINAL ARTICLE CLINICAL ASSESSMENT OF NEPHROTOXICITY ASSOCIATED WITH VANCOMYCIN TROUGH CONCENTRATIONS DURING TREATMENT OF DEEP-SEATED INFECTIONS: A RETROSPECTIVE ANALYSIS Anand Kumar Singh 1, Poonam

More information

Prevention and Treatment of Selected Opportunistic Infections: A Guidelines Update

Prevention and Treatment of Selected Opportunistic Infections: A Guidelines Update Prevention and Treatment of Selected Opportunistic Infections: A Guidelines Update Constance A. Benson, MD Professor of Medicine Division of Infectious Diseases University of California, San Diego Disclosures

More information

Pharmacodynamic indices in targeting therapy of critical infections

Pharmacodynamic indices in targeting therapy of critical infections Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective

More information

AMINOGLYCOSIDES TDM D O N E B Y

AMINOGLYCOSIDES TDM D O N E B Y AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.

More information

Challenges and controversies of Invasive fungal Infections

Challenges and controversies of Invasive fungal Infections Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases

More information

OPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY. BSAC OPAT REGIONAL WORKSHOP London 14 May 2018

OPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY. BSAC OPAT REGIONAL WORKSHOP London 14 May 2018 OPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY BSAC OPAT REGIONAL WORKSHOP London 14 May 2018 Presented by Felicity Drummond Senior Project Manager, BSAC NORS provides the most

More information

Antimykotische Therapie und TDM: ECIL 6 Guidelines

Antimykotische Therapie und TDM: ECIL 6 Guidelines Antimykotische Therapie und TDM: ECIL 6 Guidelines Disclosures Grants Gilead, Merck, Sharp & Dohme, Pfizer Consultant Amplyx, Astellas, Basilea, Gilead, Merck, Sharp & Dohme and Schering-Plough Speakers

More information

Daptomycin in Clinical Practice. Paolo Grossi

Daptomycin in Clinical Practice. Paolo Grossi Clinica delle Malattie Infettive e Tropicali Università degli Studi dell Insubria Ospedale di Circolo e Fondazione Macchi, Varese Second Opinion Infettivologica Centro Nazionale Trapianti, ISS, Roma Daptomycin

More information

EMPIRICAL PRESCRIBING GUIDELINES FOR SYSTEMIC FUNGAL INFECTIONS IN ADULTS - HH (1)/CL(G)/651/13

EMPIRICAL PRESCRIBING GUIDELINES FOR SYSTEMIC FUNGAL INFECTIONS IN ADULTS - HH (1)/CL(G)/651/13 Hampshire Hospitals NHS Foundation Trust Empirical Antifungal Prescribing Guidelines [INSERT UNIQUE POLICY IDENTIFIER] Due for latest review on January 2015. CHECK THE INTRANET FOR LATEST VERSION EMPIRICAL

More information

Pharmacology and Pharmacokinetics of TB Drugs Part I

Pharmacology and Pharmacokinetics of TB Drugs Part I Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens

More information

Searching for Clues in Infectious Diseases

Searching for Clues in Infectious Diseases Disclosure Searching for Clues in Infectious Diseases The speaker has no financial conflicts to disclose as relates to the content of this presentation John Esterly, PharmD, BCPS Northwestern Memorial

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview

More information

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE: IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE: IMPACT OF A PHARMACY DEPARTMENT-WIDE APPROACH IN A COMMUNITY HOSPITAL SETTING November 2014 Monica Dorobisz,

More information

prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures

prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures 1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam

More information

OPAT Community and Outcomes: The OPAT Service Directory and National Outcomes Registry

OPAT Community and Outcomes: The OPAT Service Directory and National Outcomes Registry OPAT Community and Outcomes: The OPAT Service Directory and National Outcomes Registry For enquiries/support: Service Directory in Action! Can BSAC sort out daily antibiotics? GP R OPAT Community and

More information

Treatment of Tuberculosis Therapeutic Drug Monitoring

Treatment of Tuberculosis Therapeutic Drug Monitoring Treatment of Tuberculosis Therapeutic Drug Monitoring 2nd European Advanced Course in Clinical Tuberculosis Dr. JWC Alffenaar, clinical pharmacologist Dept Clinical Pharmacy & Pharmacology University Medical

More information

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS

More information

Antifungal therapy guidelines

Antifungal therapy guidelines Background Invasive fungal infections (IFI) can cause significant morbidity and mortality among patients with haematological malignancies. There is good evidence for the use of antifungal prophylaxis in

More information

TDM. Measurement techniques used to determine cyclosporine level include:

TDM. Measurement techniques used to determine cyclosporine level include: TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.

More information

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro IV Vancomycin dosing and Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary Medicine Unique

More information

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric

More information

Morbid Obesity: Multi system Considerations for Acute Care

Morbid Obesity: Multi system Considerations for Acute Care Morbid Obesity: Multi system Considerations for Acute Care BRENDA ENGLER, MSN, ACNP BC, CCRN GEISINGER MEDICAL CENTER Disclosures None 1 Obesity Statistics 30 % of the adult population of Pennsylvania

More information

Antimykotische Therapie und TDM: ECIL 6 Guidelines

Antimykotische Therapie und TDM: ECIL 6 Guidelines Antimykotische Therapie und TDM: ECIL 6 Guidelines Disclosures Grants Gilead, Merck, Sharp & Dohme, Pfizer Consultant Amplyx, Astellas, Basilea, Gilead, Merck, Sharp & Dohme and Schering-Plough Speakers

More information

Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino Jul-Aug; 21(4):423-7

Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino Jul-Aug; 21(4):423-7 AMINOGLYCOSIDES Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino. 2007 Jul-Aug; 21(4):423-7 http://www.ncbi.nlm.nih.gov/pubmed/17882910 Evaluation of the in-vivo

More information

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia

More information

GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC SETTINGS GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC

GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC SETTINGS GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC SETTINGS 1 1 Gentamicin: Guidelines for Once Daily Usage in Adult and Paediatric Settings These guidelines were designed by the Gentamicin

More information

Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations

Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations Interdisciplinary Perspectives on Infectious Diseases Volume 2013, Article ID 839456, 8 pages http://dx.doi.org/10.1155/2013/839456 Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated

More information

D DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.

D DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1. Journal of Pharmacy and Pharmacology 2 (2014) 713-721 doi: 10.17265/2328-2150/2014.12.004 D DAVID PUBLISHING Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within

More information

CAT. Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators. Apr. Glynis Frans Supervisor: Prof. Apr.

CAT. Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators. Apr. Glynis Frans Supervisor: Prof. Apr. CAT Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators Apr. Glynis Frans Supervisor: Prof. Apr. Katrien Lagrou 1. What are the current guidelines and recommendations on TDM for

More information

Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis

Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis Journal of Antimicrobial Chemotherapy Advance Access published October 25, 2007 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkm410 Community-associated MRSA (CA-MRSA): an emerging pathogen in

More information

Terapia delle infezioni da Pseudomonas aeruginosa MDR

Terapia delle infezioni da Pseudomonas aeruginosa MDR Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa

More information

New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. D. C. Shanson

New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. D. C. Shanson Journal of Antimicrobial Chemotherapy (1998) 42, 292 296 New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis JAC D. C. Shanson Microbiology Department,

More information

Disclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past

Disclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.

More information

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018 Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million

More information

Guidelines for Monitoring of Vancomycin Serum Concentrations in Adult Patients

Guidelines for Monitoring of Vancomycin Serum Concentrations in Adult Patients Guidelines for Monitoring of Vancomycin Serum Concentrations in Adult Patients Guidelines developed by UWHC Department of Pharmacy Author: Cindy Gaston, RPh, PharmD Reviewed by: Antimicrobial Subcommittee,

More information

Resurgence of older oral therapies in OPAT: options for OPAT sparing

Resurgence of older oral therapies in OPAT: options for OPAT sparing Resurgence of older oral therapies in OPAT: options for OPAT sparing Dr Carolyn Hemsley Consultant in Infectious Disease and Microbiology, Guy s and St Thomas, London Why do we intravenous therapy? Evidence

More information

Vancomycin Drug Class 1

Vancomycin Drug Class 1 Drug Class 1 Antibiotic glycopeptide Spectrum 1 Cross Sensitivities / Allergies 1 Refer to product monograph for complete spectrum Gram positive pathogens (e.g., S. aureus, Enterococcus, S. viridans, methicillinresistant

More information

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology Journal of Antimicrobial Chemotherapy Advance Access published December 29, 2013 J Antimicrob Chemother doi:10.1093/jac/dkt508 Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the

More information

Management of Drug-resistant Tuberculosis (DR-TB)

Management of Drug-resistant Tuberculosis (DR-TB) Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical

More information

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus

More information